Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
JW (Cayman) Therapeutics Co. Ltd. ( (HK:2126) ) has shared an update.
JW (Cayman) Therapeutics Co. Ltd has announced the current composition of its board of directors, which includes one executive director, four non-executive directors and three independent non-executive directors, with Cheng Liu serving as chairman. The company has also detailed the membership and leadership of its four key board committees—audit, remuneration, nomination, and business development and strategy—clarifying governance responsibilities and oversight structures, which underscores its ongoing efforts to strengthen corporate governance and strategic decision-making for stakeholders.
The most recent analyst rating on (HK:2126) stock is a Hold with a HK$3.00 price target. To see the full list of analyst forecasts on JW (Cayman) Therapeutics Co. Ltd. stock, see the HK:2126 Stock Forecast page.
More about JW (Cayman) Therapeutics Co. Ltd.
JW (Cayman) Therapeutics Co. Ltd is a biotechnology company focused on developing and commercializing innovative cell-based immunotherapies, operating primarily in China with a focus on oncology treatments and advanced therapeutic platforms.
Average Trading Volume: 1,540,027
Technical Sentiment Signal: Sell
Current Market Cap: HK$1.11B
See more data about 2126 stock on TipRanks’ Stock Analysis page.